HEALTHCARE

Personal experience motivated Roy Goldenberg to become Israel director of TOM Tikkun Olam Makers. "TOM will be one of the biggest organizations to come out of Israel," he says.

The death of a cancer patient spurred Dr. Adi Zoref-Lorenz into developing the OHI index, which allows the diagnosis of the HLH side effect from cancer immunotherapy, based on two blood tests.

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Insightec COO and general manager Eyal Zadicario tells "Globes" about himself and the Israeli ultrasound company's long battle to change the medical world.

Navina equips clinicians and care teams with real-time, data-driven insights that improve the quality of care and financial outcomes.

"We know nothing about the female reproductive system," says Dr. Ola Gutzeit of Rambam Hospital. She seeks to change that, and hence change IVF for the better.

The nine startups participated in the Dangoor HealthTech Academy, a program that connects Israeli startups with the UK healthcare system.

In an exclusive interview Richard Burke talks about the murder of the company's CEO, Donald Trump, his love for Israel, and investment in Israeli startup Korro AI.

Prof. Yifat Merbl of the Weizmann Institute and her team have found a natural source of anti-microbial substances in the "garbage can" of human cells.

In Israel for IATI's MIXiii International Life Science and Health-Tech week, the US investor talks about his life science portfolio and the opportunities Israel must seize.

85% of the senior figures in venture capital funds in Israel's biomed sector see investments by companies and foreign funds increasing in 2025 compared with 2024.

The US medical device company will pay up to $540 million for the Rehovot-based intravascular ultrasound device developer for treating high blood pressure.

Last year "Newsweek" ranked Sheba Medical Center in ninth place and previously it was in tenth place.

Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.

The Israeli pharmaceutical company's debt fell to $17.8 billion at the end of 2024, down from $19.8 billion at the end of the 2023.

The Israeli company aims to disrupt the optical industry by digitalizing the lens coating process.

The company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.

The Israeli pharmaceuticals company reported strong fourth quarter results but its 2025 outlook did not meet expectations.

The former Moderna CMO, who led development of the company's Covid vaccine, tells "Globes" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.

The company is also announcing the launch of a powerful new clinical documentation improvement (CDI) product, Eleos Compliance.

Veteran Israeli venture capitalist Amir Gal-Or is launching an ambitious AI-enabled system that will produce personalized DNA-based recommendations.

The medical controversy on the matter in Israel exposes the problem of obtaining accurate clinical data on the effectiveness of medical cannabis for treating all conditions.

The Or Akiva-based medical device company is developing the Nautilus device for aneurysm treatment.

Bank of America has raised Teva's price target to $26 per share and Cantor Fitzgerald has raised Wix's price target to $260 per share.

Yaron Yakobi and Tzahi Hagag will become parties at interest in the company led by Ehud Barak and Alexander Rabinovich. ,

The Israeli pharmaceutical company's market cap gained $5 billion in one Wall Street session boosting Israeli pension funds by hundreds of millions of dollars.

Teva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn's disease.

The winning firm is Rubinstein Ofer with Canadian architects Tye Farrow.

Remepy co-founder Michal Tsur told the Israel Business Conference about the therapy revolution whose time has come.

The Israeli pharmaceutical firm is selling its 51% stake in the joint venture to private equity firm J-Will Partners.